BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260703T090227Z
CREATED:20260703T090227Z
LAST-MODIFIED:20260703T090227Z
UID:43883-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:The 9th RNA-Targeted Drug Discovery & Development Summit returns to Boston\, MA\, on November 10–12\, 2026\, as the industry’s only dedicated meeting focused exclusively on RNA-targeted small molecules\, bringing together leading minds from biotech\, pharma and academia to advance the next generation of RNA-focused therapeutics. \nAs momentum continues to build across the field\, driven by recent clinical progress and increasing investment in RNA-targeted approaches\, the summit will explore the latest advances in direct RNA binding\, splice modulation\, RNA degradation\, covalent translation inhibition\, epitranscriptomic regulation and condensate biology. Attendees will gain valuable insights into how researchers are overcoming historic challenges in RNA druggability to develop new treatments for oncology\, rare genetic diseases and neurodegenerative disorders. \nA refreshed 2026 agenda will feature expert-led presentations\, case studies\, panel discussions and interactive workshops covering functional RNA target selection\, structure-guided design\, productive chemical space and emerging RNA-targeting technologies. Delegates will also discover practical strategies for improving screening approaches\, measuring selectivity\, validating targets and accelerating translation from discovery into clinical development. \nThe summit is expected to welcome 80+ RNA-targeted drug discovery experts and 22+ world-class speakers\, including representatives from PTC Therapeutics\, AstraZeneca\, Sanofi\, ReviR Therapeutics\, Remix Therapeutics\, Arrakis Therapeutics\, Dewpoint Therapeutics and Syrna Therapeutics. Through dedicated networking opportunities and collaborative discussions\, attendees will connect with the scientists\, innovators and decision-makers shaping the future of RNA-targeted medicines. \nWhether you are focused on RNA biology\, medicinal chemistry\, drug discovery\, translational research or therapeutic development\, this summit offers an unparalleled opportunity to access cutting-edge data\, exchange ideas with pioneers in the field and help drive the next wave of innovation in RNA-targeted small molecule therapeutics. As the field continues to mature\, the 9th RNA-Targeted Drug Discovery & Development Summit remains the must-attend forum for staying at the forefront of RNA drug discovery.
URL:https://www.pharmajournalist.com/event/9th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260709T124430Z
CREATED:20260709T124339Z
LAST-MODIFIED:20260709T124430Z
UID:43911-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:9th Lab Asset & Facility Management Summit
DESCRIPTION:The 9th Lab Asset & Facility Management (LAFM) Summit 2026 is the leading industry forum dedicated to helping pharmaceutical and biotech organizations optimize lab operations\, asset management\, facilities\, engineering\, and research infrastructure. Taking place in Boston\, MA from November 10–12\, 2026\, the flagship event brings together 190+ senior leaders and decision-makers responsible for creating efficient\, resilient\, and high-performing R&D environments. \nAs scientific research becomes increasingly complex and organizations face growing pressure to do more with less\, LAFM provides a unique platform to explore practical strategies that improve operational efficiency\, maximize asset performance\, strengthen cross-functional collaboration\, and ultimately give scientists more time to focus on breakthrough research. \nJoin us to gain actionable insights through over 28 real-world case studies\, interactive discussions\, peer-to-peer benchmarking\, and hands-on workshops designed to address the most pressing challenges facing lab operations and facility management teams today. The agenda features dedicated content covering both laboratory operations and site-wide management\, helping attendees discover proven approaches to streamlining workflows\, improving maintenance strategies\, enhancing asset visibility\, and building more future-ready research environments. \nThe 2026 agenda also introduces innovative networking and learning formats\, including the LAFM Exchange and the R&D Operations Action Day\, giving participants more opportunities to engage with peers\, share experiences\, and leave with practical frameworks they can implement immediately within their own organizations. \nBringing together experts from leading organizations including Pfizer\, Takeda\, Novartis\, Regeneron\, Sanofi\, Boehringer Ingelheim\, Gilead Sciences\, and Eli Lilly\, LAFM offers an unrivalled opportunity to connect with the people shaping the future of laboratory and facility operations across the life sciences industry. Whether your goal is to increase operational efficiency\, improve facility performance\, support scientific teams more effectively\, or benchmark your strategy against industry leaders\, LAFM is the place to learn\, connect\, and drive meaningful impact across your organization. \nTo know more visit: https://ter.li/mnzyk67w
URL:https://www.pharmajournalist.com/event/9th-lab-asset-facility-management-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261110
DTEND;VALUE=DATE:20261113
DTSTAMP:20260827T133639Z
CREATED:20260709T144427Z
LAST-MODIFIED:20260827T133639Z
UID:43942-1794268800-1794527999@www.pharmajournalist.com
SUMMARY:2nd World RNA-Based Therapeutics & Vaccines Summit South Korea
DESCRIPTION:Driven by South Korea’s government making strategic investments in mRNA platforms and growing collaboration between global pharma and local biotech innovators\, the field is experiencing renewed development momentum. This is placing the region as a key hotspot for global mRNA innovation and interest. \nUniquely positioned as the industry’s most comprehensive biopharma forum\, the 2nd World RNA-Based Therapeutic & Vaccine Summit South Korea brings together global and local leaders to share first-hand insights into cutting-edge mRNA modalities\, delivery technologies\, and manufacturing excellence\, to progress mRNA medicines to patients faster.
URL:https://www.pharmajournalist.com/event/2nd-world-rna-based-therapeutics-vaccines-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261116
DTEND;VALUE=DATE:20261118
DTSTAMP:20260805T093959Z
CREATED:20260804T140412Z
LAST-MODIFIED:20260805T093959Z
UID:44087-1794787200-1794959999@www.pharmajournalist.com
SUMMARY:Biomarker Operations & Biospecimen Management Summit
DESCRIPTION:Hot off the press: The biomarker operations and biospecimen community finally has its own dedicated forum. \nIntroducing the inaugural Biomarker Operations & Biospecimen Management Summit\, the industry’s first\, purpose-built meeting for the heads\, VPs and leading stakeholders at pharma and biotech directly responsible for biospecimen and biomarker delivery. \nView the newly released agenda:  https://ter.li/p9sor70u \nWith trials growing in complexity\, rapidly expanding globally and becoming more data-intensive\, biomarker operations has emerged as the critical function for teams looking to advance biomarker- and multi-omics-driven therapies to market. \nAnswering the industry’s call to unite those collecting\, tracking and/or translating biospecimen data\, this meeting arrives at a pivotal moment. \nYou can expect to join 80+ experts to strategize on: \n\nElevating pre-analytical quality and site collection practices\, protecting biomarker signal integrity from the very first draw\nSecuring and storing biospecimens for the long term\, building acquisition\, biobanking\, and disposition strategies that balance cost\, compliance\, and future scientific value\nStreamlining biosample logistics\, kit management and vendor sourcing\, cutting waste and tracking errors so every sample reaches the right lab\, on time\nNavigating consent complexity and evolving regulation\, including IVDR and ICH E6(R3)\, to keep biospecimens compliant and usable for research\, long after collection\nEmbedding FAIR data principles and AI-driven automation into biomarker workflows\, replacing manual reconciliation with systems that accelerate decision-making\n\nAlongside this\, hear best-in-class strategies from AstraZeneca\, Regeneron\, Moderna\, BioNTech\, and Bristol Myers Squibb and real-time updates from Biospecimen Management Consortium (BMC). \nJoin us in collaboratively building the future playbook that will define the standards for precision medicine therapies. \nRegistration is complimentary* for qualifying biopharma and researchers. Visit the website to reserve your spot: https://ter.li/6v47cb7t
URL:https://www.pharmajournalist.com/event/biomarker-operations-biospecimen-management-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261117
DTEND;VALUE=DATE:20261120
DTSTAMP:20260813T160131Z
CREATED:20260813T160131Z
LAST-MODIFIED:20260813T160131Z
UID:44184-1794873600-1795132799@www.pharmajournalist.com
SUMMARY:2nd Model-Informed Drug Development Summit 2026
DESCRIPTION:As model-informed drug development (MIDD) becomes increasingly central to modern drug development strategy\, organizations are under growing pressure to leverage quantitative approaches that accelerate timelines\, reduce risk\, and improve regulatory and clinical success. The 2nd Model-Informed Drug Development Summit\, taking place November 17-19\, 2026\, in Boston\, MA\, brings together senior leaders in pharmacometrics\, clinical pharmacology\, quantitative sciences\, translational medicine\, and regulatory science to explore how modelling is transforming decision-making across the entire development lifecycle. \nDesigned as an intimate and highly interactive forum\, this summit moves beyond traditional large-scale industry meetings to provide meaningful peer-to-peer networking\, practical case studies\, and candid discussions on the real-world challenges of implementing MIDD strategies. Attendees will gain insights from leading organizations including FDA\, Health Canada\, Sanofi\, Eli Lilly\, GSK\, AbbVie\, Novartis\, Amgen\, Genentech\, Gilead Sciences\, BMS\, Astellas Pharma\, Vertex Pharmaceuticals\, Johnson & Johnson\, and Genmab. \nThe agenda explores the latest industry developments\, including implementation of the finalized ICH M15 guideline\, the growing role of quantitative systems pharmacology (QSP)\, advances in AI-enabled modelling\, and the use of real-world evidence to strengthen development decisions. Through case studies\, panel discussions\, workshops\, and roundtable sessions\, attendees will learn how to optimize dose selection\, improve trial design\, accelerate rare disease programs\, validate model outputs\, demonstrate return on investment from MIDD initiatives\, and strengthen regulatory submissions. \nIn addition to the main conference\, dedicated workshops will examine how to integrate pharmacometrics\, QSP\, machine learning\, and AI into connected modelling ecosystems\, while also addressing the challenge of building internal and external stakeholder confidence in modelling approaches. \nWith more than 60 senior industry leaders expected to attend\, the summit offers a unique opportunity to benchmark strategies\, share best practices\, build valuable partnerships\, and stay ahead of evolving regulatory and scientific expectations. Whether you are advancing innovative therapies\, refining quantitative development strategies\, or exploring the future role of AI in drug development\, this event provides the practical insights and connections needed to maximize the impact of model-informed approaches across your organization. \nTo learn more about the event and register online click here.
URL:https://www.pharmajournalist.com/event/2nd-model-informed-drug-development-summit-2026/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261203
DTSTAMP:20260915T005613Z
CREATED:20260811T103702Z
LAST-MODIFIED:20260915T005613Z
UID:44144-1795996800-1796255999@www.pharmajournalist.com
SUMMARY:Novel CNS Biomarkers Summit Europe
DESCRIPTION:Introducing Europe’s first CNS Biomarker Forum. The Novel CNS Biomarkers Summit Europe is the only European meeting dedicated exclusively to advancing fluid\, imaging\, and digital biomarkers for CNS drug development. Bringing together biomarker\, translational medicine\, neuroscience\, and clinical development leaders\, the summit focuses on accelerating the discovery\, validation\, and implementation of next-generation biomarkers across neurodegenerative and neurological diseases. \nAs landmark advances in blood-based Alzheimer’s diagnostics\, digital biomarkers\, multimodal approaches\, and precision medicine continue to reshape the field\, attendees at the Novel CNS Biomarkers Summit Europe will explore strategies to improve patient stratification\, demonstrate target engagement\, generate earlier efficacy signals\, and de-risk CNS drug development programmes. \nCompanies attending the Novel CNS Biomarkers Summit Europe: \n\nRoche\n\n\nUCB\n\n\nLundbeck\n\n\nServier\n\n\nNRG Therapeutics\n\n\nImmunic Therapeutics\n\n\nProgenra\n\n\nSaniona\n\n\nBial\n\n…and more! \nWhy attend the Novel CNS Biomarkers Summit Europe? \n\nJoin 60+ biomarker and translational medicine leaders\n\n\nGain insights from 17+ expert speakers\n\n\nExplore biomarker strategies across 6+ CNS indications\n\n\nParticipate in interactive workshops and networking opportunities\n\nDiscover the brand-new event programme now for more information on sessions and how to register your place.
URL:https://www.pharmajournalist.com/event/novel-cns-biomarkers-summit-europe/
LOCATION:The Hilton London Olympia\, 380 Kensington High St\, Kensington\, London\, W14 8N\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260805T090545Z
CREATED:20260805T090501Z
LAST-MODIFIED:20260805T090545Z
UID:44111-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:8th CNS Drug Delivery Summit
DESCRIPTION:The 8th CNS Drug Delivery Summit is the leading industry forum dedicated to overcoming the challenges of delivering therapeutics across the blood-brain barrier and into the central nervous system. \nBringing together experts from biopharma\, biotech\, and academia\, the summit will explore the latest advances in drug delivery technologies\, including nanoparticles\, antibody shuttles\, gene therapy vectors\, focused ultrasound\, and intranasal delivery. Attendees will gain practical insights into improving drug penetration\, optimising biodistribution\, and advancing therapies for neurological and neurodegenerative diseases. \nThrough scientific presentations\, case studies\, and interactive discussions\, the event will address key translational\, clinical\, manufacturing\, and regulatory challenges while showcasing innovative approaches that can accelerate CNS drug development. \nJoin a collaborative community of drug developers\, technology innovators\, and scientific leaders committed to unlocking the next generation of CNS therapies and improving outcomes for patients worldwide. \nFind out more today: https://ter.li/08gi5jio
URL:https://www.pharmajournalist.com/event/8th-cns-drug-delivery-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260821T102547Z
CREATED:20260821T102547Z
LAST-MODIFIED:20260821T102547Z
UID:44216-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy for Autoimmune Disease Summit
DESCRIPTION:The 4th Cell Therapy for Autoimmune Disease Summit is the premier industry forum uniting biopharma leaders\, clinical innovators\, and scientific pioneers dedicated to advancing the next generation of cell therapies for autoimmune diseases. As the field progresses beyond early proof-of-concept studies and begins to generate increasingly robust clinical data\, organizations are shifting their focus toward the critical challenges that will determine long-term success. These include identifying optimal targets\, improving clinical translation\, enhancing manufacturing scalability\, ensuring patient safety\, navigating evolving regulatory pathways\, and developing sustainable commercialization strategies. \nTaking place December 1-3\, 2026\, in Philadelphia\, the summit provides a unique opportunity for stakeholders across biotech\, pharma\, academia\, translational research\, and clinical development to come together and share lessons learned from the forefront of autoimmune cell therapy innovation. With increasing momentum behind cell-based approaches for autoimmune indications\, attendees will gain practical insights into how leading organizations are overcoming development hurdles and positioning their programs for future success. \nThe agenda showcases the latest breakthroughs across a range of therapeutic modalities\, including CAR-T\, NK\, Treg\, MSC\, and emerging in vivo cell therapy approaches. Expert speakers from organizations such as Artiva Biotherapeutics\, Kite Pharma\, Cabaletta Bio\, Sail Biomedicines\, Mesoblast\, Orca Bio\, and other leading innovators will present real-world case studies\, clinical updates\, and strategic perspectives. Discussions will focus on analyzing increasingly mature clinical datasets\, expanding cell therapy applications beyond oncology\, exploring novel targets beyond CD19\, leveraging biomarkers and endpoints to optimize development\, and creating scalable manufacturing and delivery strategies to bring therapies to larger patient populations. \nIn addition to its comprehensive scientific program\, the summit offers extensive networking opportunities designed to foster collaboration across the autoimmune cell therapy community. Attendees will have the chance to connect with peers\, potential partners\, investors\, solution providers\, and key opinion leaders who are addressing similar scientific\, clinical\, operational\, and commercial challenges. Through interactive roundtable discussions\, dedicated networking sessions\, and informal meetings\, participants can exchange ideas\, establish valuable partnerships\, and build relationships that help accelerate the development and delivery of transformative cell therapies for patients living with autoimmune diseases. \nTo know more visit: https://ter.li/j0rhnmgf
URL:https://www.pharmajournalist.com/event/4th-cell-therapy-for-autoimmune-disease-summit/
LOCATION:Hilton Philadelphia City Avenue\, 4200 City Ave\, Philadelphia\, PA\, 19131\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260827T093413Z
CREATED:20260827T093413Z
LAST-MODIFIED:20260827T093413Z
UID:44259-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:10th Antifibrotic Drug Development Summit 2026
DESCRIPTION:Antifibrotic Drug Development Summit 2026 | December 1-3\, 2026 | Boston\, MA\, USA \nThe 10th Antifibrotic Drug Development Summit is the industry’s only dedicated forum focused on cross-indication antifibrotic drug development\, bringing together 60+ senior leaders across discovery\, preclinical\, translational\, biomarker\, and early clinical development. \nThis landmark anniversary meeting will explore how shared fibrosis biology\, predictive biomarkers\, human-relevant models\, and fibrosis resolution mechanisms can accelerate the development of next-generation therapies across lung\, liver\, kidney\, cardiac\, skin\, gut\, and systemic fibrosis indications.  \nFeaturing 23+ expert speakers from leading organizations including Madrigal Pharmaceuticals\, AbbVie\, aTyr Pharma\, Pfizer\, Takeda\, Novartis\, Arda Therapeutics\, and Tribune Therapeutics\, attendees will gain actionable insights into target identification\, translational strategies\, patient stratification\, and cross-indication expansion. \nThe event includes our highly anticipated three interactive pre-conference workshops\, two days of scientific presentations\, panel discussions\, and dedicated networking opportunities designed to foster collaboration across the fibrosis ecosystem. \nWho Should Attend? \n\nDiscovery & preclinical scientists\nTranslational researchers\nBiomarker specialists\nClinical development teams\nFibrosis-focused biotech and pharma leaders\n\nRegister and learn more: https://ter.li/5u0tkg56
URL:https://www.pharmajournalist.com/event/10th-antifibrotic-drug-development-summit-2026/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261204
DTSTAMP:20260915T005142Z
CREATED:20260915T005142Z
LAST-MODIFIED:20260915T005142Z
UID:44357-1796083200-1796342399@www.pharmajournalist.com
SUMMARY:Amylin-Based Therapeutics Summit
DESCRIPTION:Amylin‑Based Therapeutics Summit | December 1-3\, 2026 | Boston\, MA\nThe amylin analog space is rapidly expanding in 2026\, with new companies entering the field\, stealth programs beginning to emerge\, and major investment from Roche–Zealand Pharma and AbbVie–Gubra reinforcing growing confidence in the modality. With biology still being unlocked and multiple development paths on the table\, there remains headroom to define best‑in‑class amylin therapeutics\, open new indications\, and shape how this therapeutic area will deliver differentiated\, durable benefit. For companies that get the science right\, the competitive upside is significant. \nThe inaugural Amylin‑Based Therapeutics Summit 2026 arrives at this critical inflection point. This is the first and only industry‑dedicated forum bringing biopharma and academia together to dive deep and explore the full breadth of amylin drug development – from foundational receptor biology to late‑stage clinical strategy. Across two immersive days\, learn from and connect with pioneering minds from Novo Nordisk\, Eli Lilly\, Zealand Pharma\, iBio\, I2O Therapeutics and emerging innovators who are collectively shaping the field. \nView the full event guide: https://ter.li/2ao09t84
URL:https://www.pharmajournalist.com/event/amylin-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T155514Z
CREATED:20260813T155514Z
LAST-MODIFIED:20260813T155514Z
UID:44179-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:World CNS Summit South Korea
DESCRIPTION:The World CNS Summit South Korea is the premier industry-focused forum dedicated to advancing targeted\, mechanism-differentiated therapies for neurodegenerative\, rare neurodevelopmental\, and neuropsychiatric disorders. As South Korea emerges as a major center for neuroscience innovation\, the summit convenes biopharma leaders\, translational scientists\, and drug developers to explore the next generation of CNS therapeutics and accelerate progress from discovery through early clinical development. \nThe agenda highlights advances in disease-modifying approaches\, blood-brain barrier delivery technologies\, RNA-based therapeutics\, gene therapies\, neuroinflammation\, biomarkers\, and novel targets beyond traditional amyloid and tau pathways. Attendees will gain insights from leading organizations including ABL Bio\, AriBio\, Johnson & Johnson\, Eli Lilly\, Novartis\, Takeda\, AbbVie\, Lundbeck\, Angelini Pharma and many more. \nDesigned to foster meaningful scientific exchange and strategic collaboration\, the summit provides a valuable platform to connect with Korean biotech innovators\, global pharmaceutical companies\, and external innovation leaders evaluating the next wave of CNS opportunities. For decision-makers shaping neuroscience pipelines\, partnerships\, and licensing strategies\, it offers a focused view of the technologies\, modalities\, and therapeutic approaches driving the future of CNS drug development. \nFind out more today: https://ter.li/jrf94t4n
URL:https://www.pharmajournalist.com/event/world-cns-summit-south-korea/
LOCATION:Grand Hyatt Incheon 208 Yeongjonghaeannam-ro\, 321 Beon-gil\, Yeongjong-gu\, 23358\,  Incheon South Korea
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261208
DTEND;VALUE=DATE:20261211
DTSTAMP:20260813T160546Z
CREATED:20260813T160546Z
LAST-MODIFIED:20260813T160546Z
UID:44189-1796688000-1796947199@www.pharmajournalist.com
SUMMARY:10th Complement-Based Drug Development Summit
DESCRIPTION:The 10th Complement-Based Drug Development Summit returns at a pivotal moment as the field shifts from validating complement biology to maximizing its clinical and commercial potential. As pipelines expand beyond C3 and C5 and competition intensifies\, developers are focused on identifying the right targets\, modalities\, and indications to drive differentiation and patient impact. Recent milestones\, including Regeneron’s cemdisiran advancing through FDA and EMA review and Biogen’s acquisition of Apellis\, highlight the growing momentum and investment shaping the next era of complement therapeutics. \nAs the industry’s only dedicated forum uniting complement leaders\, this meeting will address the strategic and scientific priorities shaping the next generation of complement therapeutics\, including: \n\nAdvancing clinical success through biomarker innovation\, improved target engagement strategies\, robust trial design\, and smarter indication selection to de-risk development\n\n\nBenchmarking next-generation modalities across siRNA\, gene therapy\, biologics\, and novel delivery technologies to improve durability\, efficacy\, safety\, and patient outcomes\n\n\nExpanding beyond C3 and C5 to evaluate intracellular complement biology\, emerging targets\, novel mechanisms\, and combination approaches shaping the next generation of complement therapeutics\n\n\nUnlocking growth beyond renal disease by assessing the translational and clinical opportunity across neurodegenerative\, ocular\, autoimmune\, haematological\, oncology\, and acute indications\n\nWhat to Expect: \n\n80+ Experts Dedicated to Complement\n\n\n18+ Data-Driven Presentations\n\n\n7+ Hours of Meaningful Networking\n\n\n2 Discussion-Led Workshops\n\n\n1 Scientific Poster Session\n\nBringing together biotech innovators\, pharma leaders\, and academic KOLs\, this industry-led anniversary meeting provides a focused opportunity to advance novel targets\, refine modality strategy\, navigate clinical development\, and expand into new indications. \nBy attending\, you’ll be in the room with: Annexon Biosciences\, Apellis Pharmaceuticals\, Cascade Biotechnology\, Complement Therapeutics\, Graviton Biosciences\, Genentech\, Grid Therapeutics\, Ikarovec\, Inflarx\, Regeneron\, Ripple Therapeutics\, Sanofi and more! \nAcross 3 days of discussion-led workshops\, data-driven presentations\, clinical insights\, and expert panels\, engage with the leaders behind renal readouts\, next-generation targets\, and emerging CNS and ophthalmology programs to benchmark your approach\, strengthen differentiation\, and build partnerships that de-risk complement drug development. \nDiscover the 10th Anniversary Meeting program here: https://ter.li/2yscb7oh
URL:https://www.pharmajournalist.com/event/10th-complement-based-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261209
DTEND;VALUE=DATE:20261211
DTSTAMP:20261001T143517Z
CREATED:20261001T143450Z
LAST-MODIFIED:20261001T143517Z
UID:44456-1796774400-1796947199@www.pharmajournalist.com
SUMMARY:3rd Obesity & Weight Loss Drug Development Summit West
DESCRIPTION:Optimizing Tolerability\, Quality of Weight Loss & Personalized Therapies to Drive Competitive Drug Development \nAs obesity drug development enters a defining new chapter\, the race is no longer about developing the next GLP-1\, but delivering the next breakthrough in tolerability\, muscle preservation\, patient adherence\, precision medicine\, and long-term outcomes. With hundreds of obesity assets in development and billions of dollars invested in the space\, 2026 is a pivotal moment for companies to differentiate their pipelines\, benchmark their strategies\, and secure their position in the market. \nThe 3rd Obesity & Weight Loss Drug Development Summit West is where the industry’s most innovative pharma and biotech leaders come together to answer the questions that will shape the next decade of obesity therapeutics. While many events focus on clinical readouts or broad discussions around obesity care\, this summit is dedicated to the practical challenges and strategic decisions driving drug development success. \nBringing together 80+ senior executives\, and decision-makers\, this intimate\, industry-focused forum offers unparalleled opportunities to exchange insights\, build meaningful partnerships\, and understand what today’s innovation really means for tomorrow’s therapies. If you’re serious about advancing next-generation obesity therapeutics\, this is the room you need to be in. \nTo know more visit: https://ter.li/hexuee5e
URL:https://www.pharmajournalist.com/event/3rd-obesity-weight-loss-drug-development-summit-west/
LOCATION:Sheraton Mission Valley San Diego Hotel\, 1433 Camino Del Rio South\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270122
DTSTAMP:20261002T122815Z
CREATED:20261002T122815Z
LAST-MODIFIED:20261002T122815Z
UID:44487-1800316800-1800575999@www.pharmajournalist.com
SUMMARY:5th Ophthalmic Drug Delivery Summit
DESCRIPTION:The 5th Ophthalmic Drug Delivery Summit is where the innovators behind the next generation of ocular therapies come together to solve one critical challenge: getting the right therapy to the right place in the eye. \nHear directly from leaders at Kodiak Sciences\, Re-Vana Therapeutics\, Ripple Therapeutics\, Eli Lilly\, Genentech\, Sanofi\, Astellas\, Apellis\, Beacon Therapeutics\, Kriya Therapeutics and more as they share the latest thinking on long-acting therapies\, novel delivery routes\, gene and cell therapy\, translational science and drug-device integration. \nWith clinical validation and investment accelerating across the field\, this industry-focused\, modality and indication-agnostic meeting offers a timely opportunity to benchmark emerging technologies\, learn from development successes and setbacks\, and connect with the experts tackling the biggest barriers to effective ocular delivery. \nExpect candid lessons\, emerging strategies and cross-functional perspectives spanning delivery\, formulation\, devices\, CMC\, clinical development\, regulatory strategy and commercialization. \nDon’t miss the only industry-focused\, modality\, and indication-agnostic forum dedicated to ophthalmic drug delivery. \nTo know more visit: https://ter.li/4m4gw2gg
URL:https://www.pharmajournalist.com/event/5th-ophthalmic-drug-delivery-summit/
LOCATION:Hyatt Centric Fisherman’s Wharf San Francisco\, 555 North Point St\, San Francisco\, CA\, 94133\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20260925T061157Z
CREATED:20260925T060703Z
LAST-MODIFIED:20260925T061157Z
UID:44399-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:Muscular Disorders Drug Development Summit
DESCRIPTION:Muscular Disorders Drug Development Summit | January 26-28\, 2027 | Boston\, MA \nThe muscular disease field is entering a pivotal new chapter. Following a year of significant debate around Sarepta’s Elevidys\, the industry is rapidly evolving as a new wave of gene therapies\, RNA medicines\, stem cell therapies\, and small molecules advance through development. With anticipated regulatory milestones from companies including Regenxbio\, Capricor\, and Avidity Biosciences\, alongside growing investment and renewed pharmaceutical interest\, momentum has never been stronger across muscular dystrophies\, Pompe disease\, and related myopathies. \nThe inaugural Muscular Disorders Drug Development Summit is the only industry-focused forum dedicated to helping biopharma leaders accelerate the translation\, clinical development\, and delivery of next-generation therapies for muscle disorders. \nBe the first to access the newly launched event program. \nAcross three days of expert-led presentations\, interactive discussion\, and dedicated networking\, attendees will: \n\nDiscover lessons learned from approved and late-stage muscular disease therapies\nExplore emerging modalities beyond traditional gene therapy\nAdvance biomarker strategies and functional outcome assessments\nInnovate targeted delivery approaches to improve efficacy and reduce off-target effects\nLeverage real-world data to identify meaningful\, patient-relevant endpoints\nBuild partnerships that can accelerate clinical and commercial success\n\nJoin 60+ industry experts and leading organizations including Servier\, Dyne Therapeutics\, Sanofi\, Biogen\, and Avidity Biosciences for three days of collaboration focused on overcoming the biggest challenges in muscular disorder drug development. \nWhether you’re advancing therapies for DMD\, FSHD\, DM\, LGMD\, Pompe disease\, or other rare muscle disorders\, this is the must-attend meeting to benchmark strategies\, forge new partnerships\, and help bring transformative treatments to patients faster. \nExplore the Full Agenda | Register Your Place
URL:https://www.pharmajournalist.com/event/muscular-disorders-drug-development-summit/
LOCATION:Hotel Commonwealth\, 500 Commonwealth Avenue\, Boston\, MA\, 02215\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270129
DTSTAMP:20261002T121356Z
CREATED:20261002T121356Z
LAST-MODIFIED:20261002T121356Z
UID:44484-1800921600-1801180799@www.pharmajournalist.com
SUMMARY:2nd Non-Opioid Pain Therapeutics Summit
DESCRIPTION:One year on from Vertex Pharmaceuticals’ milestone JOURNAVX® approval\, making history as the first new class of pain medicine in decades\, non-opioid pain R&D has skyrocketed as one of biopharma’s hottest areas for innovation and investment\, projected to hit $124bn by 2034. \nBringing together 150+ senior leaders across pain biology\, drug discovery\, translational science\, clinical development\, medical affairs\, business development\, venture capital\, and patient advocacy\, the 2nd Non-Opioid Pain Therapeutics Summit is the ultimate forum for drug developers to advance the next generation of pain medicines. Join experts from Vertex Pharmaceuticals\, Eli Lilly\, AbbVie\, Grünenthal\, Xenon Pharmaceuticals\, Levicept\, Tonix Pharma\, Maxona Pharmaceuticals\, 4E Therapeutics\, NIH\, Harvard Medical School\, and leading investment firms to explore emerging mechanisms\, new clinical data\, trial design innovations\, placebo mitigation strategies\, translational models\, patient-centered development approaches\, and the investment trends shaping the future of pain therapeutics. \nTo know more visit: https://ter.li/9cl7g1gn
URL:https://www.pharmajournalist.com/event/2nd-non-opioid-pain-therapeutics-summit/
LOCATION:Hyatt Regency Boston Harbor\, 101 Harborside Drive\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20270308
DTEND;VALUE=DATE:20270312
DTSTAMP:20260929T183930Z
CREATED:20260925T071331Z
LAST-MODIFIED:20260929T183930Z
UID:44434-1804464000-1804809599@www.pharmajournalist.com
SUMMARY:17th World ADC London
DESCRIPTION:17th World ADC London | 8-11th March 2027 | London\, UK\nThe preliminary agenda for the 17th World ADC London has now been released\, offering a first look at the science\, strategic insights and partnerships set to shape the future of antibody-drug conjugate (ADC) development. Taking place from 8-11th March 2027 in London\, the event will bring together more than 700 leaders from biopharma\, biotech\, academia\, investment and solution provider organisations for Europe’s largest annual gathering dedicated to the ADC community. \nAs ADCs continue to gain momentum across oncology\, the industry faces a new generation of challenges and opportunities. From overcoming resistance mechanisms and improving patient response rates to advancing differentiated designs and scaling manufacturing\, the need for collaboration and knowledge-sharing has never been greater. World ADC London provides a unique platform for the community to exchange ideas\, learn from emerging data and explore the strategies driving the next wave of innovation. \nThe programme spans the full ADC development journey\, covering discovery\, preclinical and translational development\, clinical strategy\, process and analytical development\, and manufacturing. Attendees will hear from more than 90 industry experts as they share scientific breakthroughs\, lessons learned and practical approaches to accelerating the development of safer\, more effective ADC therapies. \nMore than just a scientific meeting\, World ADC London is recognised as the annual meeting point for the global ADC community. For 17 years\, it has brought together established leaders\, emerging biotech companies\, investors and technology innovators in an environment designed to foster meaningful connections and productive discussions. Whether you are looking to benchmark your strategy\, identify new partners\, discover enabling technologies or gain a broader understanding of the competitive landscape\, the event offers unrivalled opportunities to connect with the people shaping the field. \nWith extensive networking opportunities\, dedicated partnering experiences and cutting-edge scientific content\, World ADC London remains the essential forum for anyone involved in ADC development. The newly released preliminary agenda provides an early opportunity to explore the discussions\, discoveries and connections that will help define the next chapter of ADC innovation and ultimately improve outcomes for patients worldwide. \nView the agenda here: https://ter.li/orip0z61
URL:https://www.pharmajournalist.com/event/17th-world-adc-london/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR